Item 8.01 Other Events.

On July 7, 2009, the registrant issued a press release announcing that the first patient has been enrolled in a Phase I clinical trial of the registrant's allogeneic placental-derived adherent stromal cell product, termed PLX-PAD, which is taking place at the Franziskus-Krankenhaus Hospital, Berlin.

As reported in the registrant's Current Report on Form 8-K filed on December 3, 2008, on November 28, 2008, the registrant entered into a securities purchase agreement ("Agreement"), pursuant to which the registrant sold 1,500,000 shares of its common stock ("Common Stock") at a price of $0.40 per share, for an aggregate purchase price of $600,000, and issued warrants to purchase up to an additional 1,500,000 shares of Common Stock with an exercise price of $1.00 per share. Pursuant to the Agreement, the investors have the option, by giving notice to the registrant no later than 10 business days following the release of an official announcement by the registrant that it is initiating its first human clinical trials, to purchase an additional 800,000 shares of Common Stock at a purchase price of $0.75 per share, for an aggregate purchase price of $600,000, and receive therewith warrants to purchase up to an additional 800,000 shares of Common Stock with an exercise price of $1.50 per share. The said 10 business day period commenced as of July 7, 2009 following the issuance by the registrant of the above mentioned press release.

---